Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
There are questions about vuso-vec’s supporting and confirmatory trials.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.